Company: LIMN
Filing Date: 2025-06-02
Form Type: 8-K/A
Source: 0001104659-25-055078
Chunk: 27

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-02
Form: 8-K/A
Chunk 27
---
 and corporate
governance committee. The nominating and corporate governance committee, among other things, will determine the qualifications, qualities,
skills, and other expertise required to be a director and to develop, and recommend to the Board for its approval, criteria to be considered
in selecting nominees for director, identifying and screening individuals qualified to become members of the Board and making recommendations
to the Board regarding the selection and approval of the nominees for director to be submitted to a stockholder vote at the annual meeting
of stockholders.

Certain Relationships and Related Transactions, and Director Independence

Certain relationships and
related person transactions of Iris and Liminatus are described in the Proxy Statement/Prospectus in the section titled “Certain Relationships and Related Transactions” beginning on page 222 of the Proxy Statement/Prospectus, which is incorporated
herein by reference.

Nasdaq listing rules require
that a majority of the board of directors of a company listed on Nasdaq be composed of “independent directors,” which is defined
generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship,
which, in the opinion of the company’s board of directors, would interfere with the director’s exercise of independent judgment
in carrying out the responsibilities of a director. ParentCo’s board of directors has determined that each of Dr. Eun Sook
Lee, Dr. Ji Yeon Baek and Nicholas Fernandez is an independent director under the Nasdaq listing rules and Rule 10A-3 of
the Exchange Act.

Reference is made to the disclosure
regarding director independence in the section of the Proxy Statement/Prospectus titled “Management of ParentCo Following the Business Combination” beginning on page 207 of the Proxy Statement/Prospectus, which is incorporated herein by reference.

The information set forth
under “Item 1.01 Entry into a Material Definitive Agreement” and “Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers” of this Report is incorporated
into this Item 2.01 by reference.

Legal Proceedings

From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business
activities. The Company is not a party to any material legal proceedings and is not aware of any material pending or threatened claims.

Market Price of and Dividends on the Registrant’s Common Equity